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PODIUM SESSION I:
EVERYTHING YOU WANTED TO KNOW ABOUT NICE
NI1
THREE YEARS OF NICE SCIENTIFIC ADVICE: COMPREHENSIVE ANALYSIS OF
REQUESTS TO THE PROGRAMME
Phillips S1, Crowe E2, Chivers R1, Longson C1
1National Institute for Health and Clinical Excellence, Manchester, UK, 2National Institute for
Health and Clinical Excellence, London, UK
OBJECTIVES:The NICE Scientific Advice (SA) programme was established in 2009. It
provides written advice to pharmaceutical companies and device manufacturers
about development plans for their products to ensure they produce relevant evi-
dence for future submission to NICE. Herein we present a detailed analysis of the
NICE SA programme over the past three years. METHODS: The NICE SA process
involves assessment of the manufacturer’s briefing book with input from external
clinical experts, health economists and methodological experts. Following a face-
to-face meeting between the manufacturer, the expert panel and the SA technical
team, a formal written report summarising the advice is produced. In addition,
NICE SA provides advice alongside the European Medicines Agency (EMA) and
other Health Technology Assessment (HTA) agencies. Whilst such collaborations
do not include a formal written report, advice is given verbally at joint meetings.
Following these meetings, NICE SA provides a commentary on the manufacturer’s
minutes, clarifying the issues identified from the perspective of NICE. RESULTS: To
date the programme has successfully completed 52 formal written advice projects.
Requests for advice alongside the EMA and other HTA agencies have been steadily
increasing with 13 projects completed since 2010. We produced detailed analyses
of all requests to the NICE SA programme to date. Specifically, we will report on the
types of questions posed in manufacturers’ briefing books including questions on
health economic evaluation. We will include a breakdown by therapeutic area,
frequency of requests by company, type of company, profiles of participants at
meetings, and trends over time. CONCLUSIONS:We will reflect on how the various
models of advice projects differ, how manufacturers can get the most from the
process, and how the NICE SA programme is expected to evolve.
NI2
THE USE OF OFF-LABEL COMPARATORS IN NICE APPRAISALS – AN INDIRECT
ENDORSEMENT?
Kusel J, Wong GK
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: NICE has a remit to compare new interventions to the current stan-
dard of care, which could include off-label medication. NICE must also make rec-
ommendations for new interventions within their current marketing authorisa-
tions. The objective was to assess how frequently NICE request off-label
comparators and the implications of this. METHODS: The NICE single technology
appraisal (STA) final scopes from 2010-12 were reviewed. All STAs in development
(as of 13/06/12) that had not been discontinued and had a draft or final scope were
also reviewed. Off-label comparators were identified as those that were being used
outside their license according to the European Medicines Agency or the Electronic
Medicines Compendium. RESULTS: Of 54 completed STAs reviewed, the scopes of
14 (25.9%) requested comparison to at least one off-label comparator. Of these, the
manufacturer performed this comparison in half of the cases. When the manufac-
turer did compare to an off-label comparator, the new intervention was recom-
mended in 4 cases. NICE rejected the other 3 cases for not being cost-effective,
thereby indirectly recommending the off-label alternative. Where the manufac-
turer did not perform the comparison, NICE accepted this decision in 6 (85.7%)
cases, but for the other case the ERG performed additional analysis and found the
new intervention to not be cost-effective when placed ahead of the off-label drug in
the treatment sequence. Again, NICE rejected the new intervention, and indirectly
endorsed use of the off-label comparator. Of the 73 STAs in development, 15 (20.5%)
scopes requested off-label comparators. CONCLUSIONS: NICE have rejected new
interventions in favour of off-label comparators, and given the significant number
of off-label comparators requested in ongoing appraisals they will likely have to
face similar issues in the future. If a new intervention can only be recommended
within its licence but its comparators can be indirectly recommended off-label, this
poses equality questions.
NI3
PATIENT ACCESS SCHEMES IN THE NEW NHS
Spoors J, Brown C, Johnson N, Rietveld A
RJW & Partners, Royston, Hertfordshire, UK
OBJECTIVES: Patient Access Schemes (PAS) have become an integral part of the UK
pharmaceutical environment. The research seeks to investigate the historical role
PAS have played in regard to Health Technology Appraisals (HTAs), how the mech-
anism interacts with other features of the UK funding environment, such as the
Cancer Drugs Fund (CDF), and the PAS strategies employed by pharmaceutical
companies to optimise funding recommendations. It also takes a forward look
towards any role PAS might have in a value-based pricing system, which is poten-
tially facing the UK from 2014. METHODS: We reviewed NICE Technology Apprais-
als which included a PAS from 2002 up to June 2012. We then extracted the key
information and compared and contrasted the advantages/disadvantages of dif-
ferent schemes as time has progressed. RESULTS: PAS have shifted from outcome-
based schemes to financially-based discounts. It is clear from the results that as
PAS have become more integral to the UK HTA environment, an acceptance of
confidentiality and a requirement to prove that PAS reduce uncertainty to payers
are two major developments. The research also highlights how the CDF may act as
a potential disincentive for manufacturers to engage with PAS and provide the NHS
with discounts to achieve cost-effectiveness. CONCLUSIONS: As there are set op-
portunities for manufacturers to submit PAS, it is vital that pharmaceutical com-
panies consider a PAS for the purpose of a HTA as early as possible when bringing
a new product or indication to market. The CDF, whilst expanding medicine access
to patients, may act as a disincentive for pharmaceutical companies to engage with
PAS. With a forward look to 2014, PAS are to remain a vital part of the UK HTA and
payer environment.
NI4
ANALYSIS OF STAKEHOLDERS INVOLVED IN HTA DECISION MAKING PROCESS
IN THE UK
Kalbasko A1, Andreykiv M2, Van Engen A3, Zorzi O2
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Quintiles, Hoofddorp, The
Netherlands, 3Quintiles Global Consulting, Hoofddorp, Noord-Holland, The Netherlands
OBJECTIVES: To identify the level of influence of people involved in health tech-
nology assessment (HTA) and drugs’ reimbursement in the UK (with an example of
Alzheimer’s disease) and to gain deeper understanding who these people are and
how they are interconnected within complex HTA network. METHODS: The infor-
mation about members of key national UK HTA agencies (NICE, SMC, AWMSG) was
extracted from the agencies web-sites, supplemented by information from other
sources, and categorized. Next, we analyzed Alzheimer’s disease drugs’ assess-
ments (ten HTAs of donepezil, reminyl, rivastigmine, and memantine published
from 2001 to 2012). The information about people involved in those assessments
was extracted and categorized. A scoring algorithm was developed to calculate
each person’s weight of influence based on a person’s involvement in the assess-
ments and a role within HTA agencies and other organizations. Ni3 visual analysis
software was applied to the dataset to observe and visualize interconnections.
RESULTS: We identified a segment of top influential people within the dataset and
analyzed their interconnections (involvement in multiple assessments, organiza-
tional affiliations). In total 291 people (associated with the agencies or external)
were directly or indirectly involved in HTA process. The majority of these people
(61%) were clinicians whereas 11% and 17% had economic and policy background
respectively. The average score of SMC members’ weight of influence was higher
than NICE members because SMC members were mostly involved in multiple as-
sessments. One individual was identified as connected to three key HTA agencies.
NHS, University of Southampton, University of Glasgow, and NIHR HTA were iden-
tified as key organizations indirectly involved in HTA through their members’
connections. CONCLUSIONS: HTA network is a complex system with many differ-
ent stakeholders. Zooming into this system at the people level allowed deeper
understanding who these people are, how they are interconnected and contribute
to reimbursement decision making process.
PODIUM SESSION I:
PRICING, ACCESS AND REIMBURSEMENT
PR1
COMPARISON OF CANCER DRUG PRICES IN THE UNITED STATES AND THE UK
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: To understand relative price differential for cancer drugs in the
United States and the UK. Develop implications for pricing strategy and patient
access for cancer drugs. METHODS: Ten branded cancer drugs were selected and
their prices for similar dose and packaging were compared in the United States and
the UK. Prices were analyzed for the end of 2011 and early 2012. Historical exchange
rates were used to convert British pounds to US dollars. Relative price discount was
calculated for all selected cancer drugs. KOLs and payers were interviewed to un-
derstand current and future implications of this price differential. RESULTS: The
median price discount for selected ten branded cancer drugs in the UK versus the
Unitted States was 50%. The range of discount for 10 branded cancer drugs was
27%-61%. The price discount for oral small molecule drugs was higher than for
biologics (55% vs. 45%). Since the UK is one of the few remaining free pricing
markets in Europe, other European markets are likely to have even higher dis-
counts relative to the prices in the United States. Due to rising coinsurance of
speciality products, US cancer patients bear significantly higher cost than patients
in the UK. KOL and payer interviews suggest US pricing trends for cancer drugs are
unlikely to be sustained at this level in the future. CONCLUSIONS: US cancer drug
prices are significantly higher than the prices in the UK. This price differential is
unlikely to be sustained in the future.
PR2
GUIDING PRINCIPLES FOR PROVIDING EFFECTIVE ACCESS TO MEDICINES IN
EMERGING MARKETS
Shankar R, Hickson S
IMS Consulting Group, Cambridge, UK
Chronic and non-communicable diseases are becoming a major health problem in
emerging markets. Access to effective current and pipeline treatments is limited
due to the high cost. Financing solutions will take time as these markets grow and
develop public and private insurance systems. However, governments are faced
with the immediate problem of access to treatments given limited resources. This
paper lays out guiding principles for providing effective access to these treatments
within the budget constraints faced by these governments. We looked at how
mature markets have used HTA and other pricing and market access tools to eval-
uate, prioritise and provide access to treatments. We analyse IMS data on products
launched since 2005 to find that these markets have broadly used three levers to
manage access effectively – time to reimbursement, level of access and price.
Treatments with high value to the broad population have been provided quick
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open access at premium prices. Treatments with moderate value have been pro-
vided quick access to patient sub-populations; with access increasing as prices
dropped. Treatments with low incremental value have either had to launch at
competitive prices or faced delays or significant restrictions to reimbursement till
prices dropped. While countries have used different methodologies of assessment,
the outcomes have been strikingly similar. This provides important lessons for
emerging markets. Currently many markets use blunt instruments such as across
the board price controls, which impede effective access. We posit three principles
that can help emerging markets provide effective access to medicine. First, they
must use HTA to prioritise medicines. Second, this prioritization must inform re-
source allocation. Third, they can leverage the analysis and rationale from this
prioritization and budget allocation to inform negotiations with manufacturers,
which should be based on the three levers identified above – time to reimburse-
ment, level of access and price.
PR3
DRIVERS OF PRICING AND MARKET ACCESS DECISIONS - EXAMPLES IN
SELECTED COUNTRIES
Assimakopoulos M, Jeffery M, Mukku SR
Access Partnership, London, UK
OBJECTIVES: It is extremely challenging to keep up to speed with the perpetually
dynamic Market access environment across different countries. This is difficult not
only for pharma but for payers who have the difficult task of assessing products
under tight budgetary constraints. This research is to understand the drivers influ-
encing pricing and market access decisions. METHODS: The research was con-
ducted through in-depth secondary research and interviews with stakeholders in 8
countries including the UK, Japan, Canada, France, Germany, Australia, S. Korea,
Sweden and The Netherlands. RESULTS: Analysis indicates that the value of drugs
varies by market globally due to factors of prevalence, socio-economic conditions,
unmet need, disease severity, political impact and public awareness. These factors
lead to differences in the perceived value of the same drug across countries making
it challenging for its global launch. The research indicated that most countries,
other than those that apply external price referencing use some form of value
assessment to recommend the price and reimbursement. In most mature markets
therapeutic gain measured through clinical advancement or cost effectiveness is
the critical factor. In addition these countries consider unmet needs and disease
severity as important drivers. In Sweden and the Netherlands, they consider soci-
etal perspective and Japan and Korea tend to give importance to innovation. The
only value element that does not directly relate to clinical factors and is influential
in setting the price is budget impact. CONCLUSIONS: The research indicated that
most countries, other than those that use international price referencing for setting
prices use some form of value assessment method before fixing the reimbursement
level and price of a product. It is very challenging to reward products based on their
intrinsic value without considering the current economic situation. On the contrary
innovation needs to be rewarded and encouraged for future R&D of new drugs.
PR4
TRENDS IN PRICING AND REIMBURSEMENT SCHEMES FROM 1994-2011
Sotak ML1, Haig JK2, Sulzicki M3
1OptumInsight Life Sciences, Chicago, IL, USA, 2OptumInsight Life Sciences, Burlington, ON,
Canada, 3OptumInsight, Life Sciences, Newport Beach, CA, USA
OBJECTIVES: With the increasing financial constraints facing health care systems,
innovative pricing and reimbursement schemes between payers and pharmaceu-
tical manufacturers are frequently discussed as a means of addressing the uncer-
tainty and financial concerns faced by both parties. The objectives of this study
were to review innovative pharmaceutical pricing and reimbursement schemes
across global markets and to quantify their occurrence over time. METHODS: The
literature search included two components: a search of published literature on
pharmaceutical pricing and reimbursement schemes performed in PubMed/MED-
LINE and a search of “grey” or unpublished literature conducted via the Internet.
Search terms used included “patient access schemes” and “risk-share agree-
ments”. Identified schemes were classified by country, payer, therapeutic area,
indication, drug, year, type (financial or outcomes-based) and structure (e.g., cov-
erage with evidence development). Where applicable, multiple sources were used
to obtain a full picture of a specific scheme. RESULTS: A total of 225 schemes were
identified between 1994 through 2011. 38% of the schemes were from the UK,
followed by Italy (16%) and the United States (11%). 48% of the schemes were
classified as outcomes-based and 49% as financial-based (49%). The number of
schemes identified per year remained under 10 until 2007, when 27 were identified.
The number of schemes peaked in 2009 with 33, decreasing to 17 in 2010 and 13 in
2011. Schemes for oncology products comprised 50% of all identified schemes,
followed by neurology and musculoskeletal products (10% each). Within outcomes-
based schemes, 46.2% were classified as conditional coverage and 40.5% as perfor-
mance-based reimbursement. CONCLUSIONS: Pricing and reimbursement
schemes such as risk-share agreements appear to be most frequently used in on-
cology. The UK had the most schemes per country, likely as a result of the inclusion
of patient access schemes in the NICE process. Understanding the landscape of
existing schemes can potentially aid in developing new schemes.
PODIUM SESSION I:
RESEARCH ON QUALITY OF LIFE AND PATIENT PREFERENCE METHODS
QL1
EQ-5D-5L VALUATION PROJECT FOR THE SPANISH POPULATION – A
DESCRIPTIVE OVERVIEW AND PRELIMINARY RESULTS
Ramos-Goñi J1, Errea M2, Rivero-Arias O3, Cabasés JM2, Pinto JL4
1FUNCIS, S/C Tenerife, Canary Island, Spain, 2Public University of Navarra, Pamplona, Navarra,
Spain, 3Oxford University, Oxford, UK, 4Universidad Pablo de Olavide, Sevilla, Andalucía, Spain
OBJECTIVES: The latest EQ-5D instrument, EQ-5D-5L, needs new country-specific
valuation studies to obtain a value set. Eight countries have participated on pilot
exercises to develop a final protocol. Spain is the first country where this protocol
was introduced as part of the EuroQol Valuation Project. In this presentation we
report a descriptive overview of EQ-5D-5L Spanish valuation methodology and its
preliminary results. METHODS: The survey has a two-stage sampling plan. The
first stage concentrates on the selection of Spanish regions. The 50 Spanish regions
were ordered by population size, and the first 20 regions covering 80% of the total
Spanish population were selected. In the second stage, a simple random sampling
strategy on each of the selected regions was conducted. The sample size on each
region was calculated multiplying the total sample size (1,000) by the percentage of
the population on the region respect the total population of the select 20 regions.
The final survey has three blocks of questions. The first block includes patient
characteristics (age, gender and socioeconomic status), and a respondent valuation
of own health using the EQ-5D-5L. The second block contains 10 composite time
trade-off (TTO) questions, using classic TTO for states better than death and “Lead
Time” TTO for health states considered worse than death. The last block contains
7 Discrete Choice experiment questions, where the participant has to choose be-
tween two states. Finally some questions about the difficulties of the survey are
also included. RESULTS: A detailed overview of summary statistics for the health
state valuations will be included. In addition, the impact of number of respondent
characteristics on health state valuation will also be explored. Different models
will be explored, hybrid TTO and DC model and conditional logit rescaled with TTO
values were used and compared. CONCLUSIONS: We obtained a Spanish Value set
for EQ-5D-5L.
QL2
EVALUATION OF MINIMAL CLINICALLY IMPORTANT DIFFERENCES FOR
HEALTH-RELATED QUALITY OF LIFE SCALES IN PARKINSON’S DISEASE
Winter Y, Lubbe D, Oertel W, Dodel R
Philipps University, Marburg, Hessen, Germany
OBJECTIVES: Patient-relevant outcomes are an important aspect in treatment of
Parkinson’s disease (PD), which is a common progressing neurodegenerative dis-
ease. Data on minimal clinically important differences (MCIDs) in HrQoL-measures
in PD are limited for disease-specific scales (e.g. Parkinson’s Disease Question-
naire/PDQ-39) and not available for generic HrQoL scales, such as the EuroQol. The
objective was to assess the minimal clinically important differences for the PDQ-39
and the EuroQol in patients with PD. METHODS: HrQoL data were collected from
137 consecutively recruited patients with idiopathic PD. A range of MIDs for the
PDQ-39 and the EuroQol (EQ-5D index score and visual analogue scale/VAS) was
estimated using both anchor-based and distribution-based (1/2 standard deviation
and standard error of the measure) approaches. Groups were anchored using the
quintiles of the PDQ-39, the Unified Parkinson’s Disease Rating Scale (UPDRS) and
Beck Depression Inventory (BDI). RESULTS: For EQ-5D scores, MCIDs estimated
based on the PDQ-39 and the UPDRS were 0.11 (range: 0.08 to 0.14) and 0.10 (range:
0.04 to 0.17), respectively. MCIDs for VAS scores were 5.23 (range: 3.95 to 6.44, based
on the PDQ-39) and 5.23 (range: 0.55 to 10.96, based on the UPDRS). For the PDQ-39,
MCID estimated based on the UPDRS and BDI were 7.74 (range: 3.95 to 11.51) and
7.87 (1.95 to 11.74), respectively. Distribution based MCIDs ranged from 0.09 to 0.10
(EQ-5D score), from 9.01 to 11.40 (VAS score) and from 5.79 to 8.72 (PDQ-39).
CONCLUSIONS: We identified the minimum magnitude of change that should be
considered when conducting studies to evaluate change in HrQoL of PD patients
over time. These data on minimal clinically important differences are necessary for
estimation of sample size in clinical trials, which use HrQoL as outcome measure.
Further studies are encouraged to estimate MCIDs in HrQoL outcome measures in
neurodegenerative diseases.
QL3
SIMULATIONS OF ADAPTIVE MEASUREMENT OF CHANGE FOR HEALTH
RELATED QUALITY OF LIFE ASSESMENTS IN CHRONIC CONDITIONS
Rebollo P, Castejón N, Cuervo J, Rodríguez A, Diaz H
LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain
OBJECTIVES: Health Related Quality of Life (HRQoL) is a useful outcome variable in
chronic patients follow-up. Adaptive Measurement of Change (AMC) is a technique
to measure changes at the individual level in Computer Adaptive Tests (CATs)
based on Item Response Theory. The CAT-Health system is a recently developed
CAT which measures generic HRQoL. Using AMC the CAT-Health could be used to
assess changes in a follow-up for an individual patient, something currently not
possible with the available tools. The objective was to assess, by means of simula-
tion technique, the feasibility of using AMC as a stop rule for the CAT-Health
system when doing follow-ups. METHODS: A Montecarlo simulation of the re-
sponses from 700 subjects of varying levels of HRQoL at baseline and a follow-up
with a small change in the true score of the subject (6.25 points in a 0-100 scale,
5010). The first application used the CAT Health system usual stop rules: at least
5 items, at most 15, S.E. below 1 and not being reduced more than 5%. The second
application configured the system to stop if a significant change were detected.
RESULTS: The follow-up application mean length was 16.52 items. Excluding the
most healthy subjects (not in the target population), mean length was 15.02 items.
For this sample, 75.4% of the individual changes were detected, 68% with less than
25 items.CONCLUSIONS: Increasing the maximum length of the test to 25 items for
follow-ups we can theoretically detect most changes in the HRQoL of chronic pa-
tients.
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